MCID: UTR043
MIFTS: 40

Uterine Sarcoma

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Uterine Sarcoma

MalaCards integrated aliases for Uterine Sarcoma:

Name: Uterine Sarcoma 52 54 17
Uterine Corpus Sarcoma 71
Sarcoma of the Uterus 52

Classifications:



External Ids:

UMLS 71 C0338113

Summaries for Uterine Sarcoma

MalaCards based summary : Uterine Sarcoma, also known as uterine corpus sarcoma, is related to rhabdomyosarcoma and gastrointestinal stromal tumor. An important gene associated with Uterine Sarcoma is ABCB1 (ATP Binding Cassette Subfamily B Member 1), and among its related pathways/superpathways are MicroRNAs in cancer and Imipramine/Desipramine Pathway, Pharmacokinetics. The drugs Doxorubicin and Mesna have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and breast, and related phenotypes are Decreased cell proliferation and endocrine/exocrine gland

Wikipedia : 74 The uterine sarcomas form a group of malignant tumors that arises from the smooth muscle or connective... more...

Related Diseases for Uterine Sarcoma

Diseases related to Uterine Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Related Disease Score Top Affiliating Genes
1 rhabdomyosarcoma 29.6 CCND2 ABCC1 ABCB1
2 gastrointestinal stromal tumor 28.7 WT1 CDK2 ABCB1
3 myelodysplastic syndrome 28.5 WT1 DCK CDK2 ABCB1
4 glioblastoma multiforme 28.1 CDK2 ABCC1 ABCB1
5 leukemia, acute myeloid 27.8 WT1 DCK CDK2 ABCC1 ABCB1
6 sarcoma 11.0
7 spindle cell sarcoma 11.0
8 leiomyosarcoma 11.0
9 endometrial stromal sarcoma 10.8
10 carcinosarcoma 10.8
11 leiomyoma 10.7
12 adenosarcoma 10.5
13 endometrial cancer 10.4
14 myoma 10.4
15 leiomyoma, uterine 10.4
16 myofibroma 10.4
17 uterine inversion 10.3
18 embryonal sarcoma 10.3
19 myeloid sarcoma 10.3
20 adenocarcinoma 10.3
21 neutropenia 10.3
22 soft tissue sarcoma 10.3
23 mesenchymal cell neoplasm 10.2
24 overgrowth syndrome 10.2
25 endometrial adenocarcinoma 10.2
26 uterine carcinosarcoma 10.2
27 rare tumor 10.2
28 endometrial stromal tumor 10.1
29 sarcomatosis 10.1
30 osteogenic sarcoma 10.1
31 alveolar soft part sarcoma 10.1
32 lymphoma 10.1
33 breast cancer 10.1
34 small cell carcinoma 10.1
35 fibrosarcoma 10.1
36 temporal lobe neoplasm 10.0 ABCC1 ABCB1
37 angiosarcoma 10.0
38 vaginal discharge 10.0
39 ovarian small cell carcinoma 10.0
40 colchicine resistance 10.0 ABCC1 ABCB1
41 microsporidiosis 10.0 ABCC1 ABCB1
42 cholangiolocellular carcinoma 10.0 ABCC1 ABCB1
43 hemangiopericytoma, malignant 9.9
44 adenomyosis 9.9
45 cervical cancer 9.9
46 meningioma, radiation-induced 9.9
47 meningioma, familial 9.9
48 rhabdoid tumor predisposition syndrome 1 9.9
49 endometritis 9.9
50 spinal meningioma 9.9

Graphical network of the top 20 diseases related to Uterine Sarcoma:



Diseases related to Uterine Sarcoma

Symptoms & Phenotypes for Uterine Sarcoma

GenomeRNAi Phenotypes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell proliferation GR00353-A 8.62 CDK2 DCK

MGI Mouse Phenotypes related to Uterine Sarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.65 ABCB1 CCND2 CDK2 DCK WT1
2 hematopoietic system MP:0005397 9.63 ABCB1 ABCC1 CCND2 CDK2 DCK WT1
3 immune system MP:0005387 9.43 ABCB1 ABCC1 CCND2 CDK2 DCK WT1
4 liver/biliary system MP:0005370 8.92 ABCB1 CCND2 CDK2 WT1

Drugs & Therapeutics for Uterine Sarcoma

Drugs for Uterine Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
2
Mesna Approved, Investigational Phase 3 3375-50-6 598
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
4
Gemcitabine Approved Phase 3 95058-81-4 60750
5
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
6
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
7
Lenograstim Approved, Investigational Phase 3 135968-09-1
8
Bevacizumab Approved, Investigational Phase 3 216974-75-3
9
Histamine Approved, Investigational Phase 3 51-45-6 774
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
12 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
13
Liposomal doxorubicin Phase 3 31703
14 Analgesics Phase 3
15 Cola Phase 3
16 Narcotics Phase 3
17 Anesthetics Phase 3
18 Anesthetics, General Phase 3
19 Analgesics, Opioid Phase 3
20 Adjuvants, Anesthesia Phase 3
21 Central Nervous System Depressants Phase 3
22 Anesthetics, Intravenous Phase 3
23 DHEA (Dehydroepiandrosterone) Phase 3
24 Immunologic Factors Phase 3
25 Antiviral Agents Phase 3
26 Antimetabolites Phase 3
27 Adjuvants, Immunologic Phase 3
28 Angiogenesis Inhibitors Phase 3
29 Antibodies, Monoclonal Phase 3
30 Antineoplastic Agents, Immunological Phase 3
31 Endothelial Growth Factors Phase 3
32 Mitogens Phase 3
33 Immunoglobulin G Phase 3
34 Immunoglobulins Phase 3
35 Antibodies Phase 3
36 Gastrointestinal Agents Phase 3
37 Neurotransmitter Agents Phase 3
38 Dermatologic Agents Phase 3
39 Antipruritics Phase 3
40 Histamine H1 Antagonists Phase 3
41 Serotonin Agents Phase 3
42 Histamine Antagonists Phase 3
43
Histamine Phosphate Phase 3 51-74-1 65513
44 Serotonin Antagonists Phase 3
45 Anti-Allergic Agents Phase 3
46
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
47
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
48
Progesterone Approved, Vet_approved Phase 1, Phase 2 57-83-0 5994
49
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
50
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
2 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
3 A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma Unknown status NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
4 A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
5 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
6 A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
7 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
8 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
9 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
10 A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III Completed NCT00002706 Phase 3
11 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
12 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
14 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
15 A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment Unknown status NCT01979393 Phase 2 Cabozantinib;Placebo
16 A Phase II Study of Combination Therapy of a Protracted Oral Schedule of Temozolomide and Thalidomide as First-Line or Subsequent Therapy for Patients With Metastatic, Locally Advanced or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
17 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
18 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
19 Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers Unknown status NCT02052128 Phase 1, Phase 2 onapristone
20 Systematic Nutritional Care in Patients Receiving First-line Chemotherapy for Metastatic Gynecologic Cancer in a Phase II Study Unknown status NCT00905658 Phase 2
21 Evaluation of Doxil in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
22 A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
23 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01168232 Phase 2 Ixabepilone
24 A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
25 A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
26 A Phase II Evaluation of Docetaxel and Gemcitabine Plus G-CSF in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
27 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
28 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00025220 Phase 2 Thalidomide
29 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01220609 Phase 2 Ixabepilone
30 Phase II Study of Thalidomide (NSC #66847) in Patients With Sarcomas of Gynecologic Origin Completed NCT00006005 Phase 2 thalidomide
31 A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00112489 Phase 2 carboplatin;paclitaxel
32 Continuous 5 Days Infusion of High Dose Ifosfamide and Adriamycin in Patients With Advanced Sarcoma Completed NCT00002526 Phase 2 doxorubicin hydrochloride;ifosfamide
33 A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas Completed NCT00379145 Phase 2 trabectedin
34 Phase I/II Trial, Dose Finding Combination Chemotherapy With PegLiposomal Doxorubicin (PLD) And Carboplatin In Patients With Gynecologic Tumors Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
35 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
36 A Phase II Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
37 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
38 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
39 Phase II Trial of Dolastatin-10 in Patients With Previously Untreated Recurrent/Metastatic Sarcoma Completed NCT00003778 Phase 2 dolastatin 10
40 Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas Completed NCT00227669 Phase 2 docetaxel;gemcitabine hydrochloride
41 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
42 A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma Completed NCT00238121 Phase 2 sorafenib tosylate
43 A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
44 Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
45 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
46 Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial Completed NCT00381888 Phase 2 fondaparinux sodium
47 A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
48 A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00075400 Phase 2 imatinib mesylate
49 A Phase II Trial of Radiosurgery for 1 to 3 Newly Diagnosed Brain Metastases From Renal Cell, Melanoma and Sarcoma Completed NCT00003308 Phase 2
50 High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide

Search NIH Clinical Center for Uterine Sarcoma

Genetic Tests for Uterine Sarcoma

Anatomical Context for Uterine Sarcoma

MalaCards organs/tissues related to Uterine Sarcoma:

40
Uterus, Smooth Muscle, Breast, Myeloid, Bone, Lung, Cervix

Publications for Uterine Sarcoma

Articles related to Uterine Sarcoma:

(show top 50) (show all 919)
# Title Authors PMID Year
1
Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature. 54 61
20122944 2010
2
Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. 54 61
20487633 2010
3
Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression. 54 61
19617332 2009
4
Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells. 54 61
18845169 2008
5
Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. 54 61
18813811 2008
6
Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells. 54 61
18625294 2008
7
Distinct N-glycan glycosylation of P-glycoprotein isolated from the human uterine sarcoma cell line MES-SA/Dx5. 54 61
17692467 2007
8
PDGFR-alpha as a potential therapeutic target in uterine sarcomas. 54 61
17049587 2007
9
Prognostic factors and expression of p53 and mdm-2 in uterine sarcomas. 54 61
16930603 2006
10
Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody. 54 61
16832635 2006
11
Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. 54 61
15921732 2005
12
Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells. 54 61
10867652 2000
13
COL1A1-PDGFB fusion uterine fibrosarcoma: A case report with treatment implication. 61
31921959 2020
14
Heterobinuclear copper(II)‑platinum(II) complexes with oxindolimine ligands: Interactions with DNA, and inhibition of kinase and alkaline phosphatase proteins. 61
31683126 2020
15
Investigation on the genomic characterization of uterine sarcoma for rAd-p53 combined with chemotherapy treatment. 61
32013587 2020
16
SMARCA4-deficient Uterine Sarcoma and Undifferentiated Endometrial Carcinoma Are Distinct Clinicopathologic Entities. 61
31567195 2020
17
Circulating Transcripts and Biomarkers in Uterine Tumors: Is There a Predictive Role? 61
31997106 2020
18
Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms. 61
31789001 2020
19
Incidence and outcome of occult uterine sarcoma: A multi-centre study of 18604 operations performed for presumed uterine leiomyoma. 61
31499285 2020
20
A Real-World Study on Diagnosis and Treatment of Uterine Sarcoma in Western China. 61
32015676 2020
21
Evaluation of treatment results and prognostic factors of uterine sarcoma: A single-center experience. 61
31517774 2020
22
Molecular Bio-Imaging Probe for Non-Invasive Differentiation Between Human Leiomyoma Versus Leiomyosarcoma. 61
31925772 2020
23
Development of a novel and rapid measurement system for growth differentiation factor-15, progranulin, and osteopontin in uterine sarcoma. 61
31534059 2020
24
Medicolegal Issues in Power Morcellation: Cautionary Rules for Gynecologists to Avoid Unfavorable Outcomes. 61
31954185 2020
25
Uterine mesenchymal tumours: recent advances. 61
31846533 2020
26
Serum microRNA profile enables preoperative diagnosis of uterine leiomyosarcoma. 61
31599471 2019
27
Preoperative Differentiation of Uterine Sarcoma from Leiomyoma: Comparison of Three Models Based on Different Segmentation Volumes Using Radiomics. 61
30850967 2019
28
Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma. 61
31662204 2019
29
Uterine sarcoma: An unusual but high lethal disease of gynecological malignancies. 61
31868858 2019
30
Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma using Magnetic Resonance Images: A Literature Review. 61
31817500 2019
31
Keratin 17 is a negative prognostic biomarker in high-grade endometrial carcinomas. 61
31655172 2019
32
Association Between Power Morcellation and Mortality in Women With Unexpected Uterine Cancer Undergoing Hysterectomy or Myomectomy. 61
31518176 2019
33
Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. 61
31954538 2019
34
SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association. 61
31190001 2019
35
Imaging in gynecological disease (15): clinical and ultrasound characteristics of uterine sarcoma. 61
30908820 2019
36
Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study. 61
31983102 2019
37
Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma: 10-year experience of a single institute. 61
31721462 2019
38
Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis. 61
31494310 2019
39
Chemo-sensitizing activity of natural cadinanes from Heterotheca inuloides in human uterine sarcoma cells and their in silico interaction with ABC transporters. 61
31319298 2019
40
JAZF1-SUZ12 endometrial stromal sarcoma forming subserosal masses with extraordinary uptake of fluorodeoxyglucose on positron emission tomography: a case report. 61
31615558 2019
41
Machine Learning to Differentiate T2-Weighted Hyperintense Uterine Leiomyomas from Uterine Sarcomas by Utilizing Multiparametric Magnetic Resonance Quantitative Imaging Features. 61
30661978 2019
42
Uterine Sarcoma: A Clinico-Pathological Study. 61
31686748 2019
43
Parasitic Leiomyoma on PET-CT in A Suspected Case of Uterine Sarcoma - Report on Diagnosis and Management. 61
31579245 2019
44
Hypofractionated Accelerated Chemo-radiotherapy (Chemo-HypoAR) With Cisplatin and Liposomal Doxorubicin for the Treatment of Patients With Uterine Sarcomas. 61
31471414 2019
45
Adjuvant management of operated uterine sarcomas: A single institution experience. 61
31351809 2019
46
Uterine sarcomas. 61
31235185 2019
47
Overexpression of carbonyl reductase 1 inhibits malignant behaviors and epithelial mesenchymal transition by suppressing TGF-β signaling in uterine leiomyosarcoma cells. 61
31423217 2019
48
Prognostic factors, survival outcomes, and surgical practices when dealing with uterine sarcomas: 8 years’ clinical experience 61
31298514 2019
49
Apoptotic effect of Gyejibokryunghwan on uterine sarcoma cells (SK-UT-1B). 61
31035046 2019
50
[Clinicopathological study of BCOR rearrangement in high grade endometrial stromal sarcoma]. 61
31422590 2019

Variations for Uterine Sarcoma

Expression for Uterine Sarcoma

Search GEO for disease gene expression data for Uterine Sarcoma.

Pathways for Uterine Sarcoma

Pathways related to Uterine Sarcoma according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1 12.1 CCND2 ABCC1 ABCB1
2
Show member pathways
11.56 ABCC1 ABCB1
3 11.48 DCK CDK2
4
Show member pathways
11.44 CDK2 CCND2
5
Show member pathways
11.29 ABCC1 ABCB1
6
Show member pathways
11.21 ABCC1 ABCB1
7 11.12 CDK2 CCND2
8
Show member pathways
11.06 ABCC1 ABCB1
9 10.91 CDK2 CCND2
10 10.73 ABCC1 ABCB1
11
Show member pathways
10.62 ABCC1 ABCB1
12 10.43 ABCC1 ABCB1
13 10.33 ABCC1 ABCB1
14 10.05 DCK ABCC1 ABCB1
15 9.96 ABCC1 ABCB1

GO Terms for Uterine Sarcoma

Cellular components related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein kinase holoenzyme complex GO:0000307 8.62 CDK2 CCND2

Biological processes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phospholipid translocation GO:0045332 9.16 ABCC1 ABCB1
2 transepithelial transport GO:0070633 8.96 ABCC1 ABCB1
3 export across plasma membrane GO:0140115 8.62 ABCC1 ABCB1

Molecular functions related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.62 DCK CDK2 ABCC1 ABCB1
2 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.26 ABCC1 ABCB1
3 xenobiotic transmembrane transporter activity GO:0042910 9.16 ABCC1 ABCB1
4 efflux transmembrane transporter activity GO:0015562 8.96 ABCC1 ABCB1
5 xenobiotic transmembrane transporting ATPase activity GO:0008559 8.62 ABCC1 ABCB1

Sources for Uterine Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....